In an interview with Oncology Learning Network, Udai Banerji, MD, NIHR Professor of Molecular Cancer Pharmacology, The Institute of Cancer Research, London, United Kingdom, discussed the findings and clinical significance of a phase 1 trial evaluating the use of VS-6766, a RAF/MEK inhibitor, plus defactinib, a FAK inhibitor, in patients with KRAS-mutant ovarian cancer.

Veena Shankaran, MD, MS, Discusses Financial Hardships in Patients With Metastatic CRC by HMP Global

What to Expect at the Non-Malignant Hematology Workshop at Lymphoma, Leukemia & Myeloma Congress by HMP Global

Dr Jabbour on Management of Ph+ and Ph-like ALL by HMP Global

Christopher Crane, MD, Discusses Benefits of Long-Course Vs Short-Course RT for Rectal Cancer by HMP Global

CAR T-Cell Therapy Promising for Relapsed, Refractory Large B-Cell NHL by HMP Global

Long-term Follow Up of First-line NALIRIFOX in Pancreatic Cancer by HMP Global

Interim Analysis Suggests Correlation Between Ponatinib Dosing and Efficacy in CML by HMP Global

Petros Grivas, MD, PhD, talks about the importance of the IMvigor010 clinical trial, which assessed the use of adjuvant atezolizumab in patients with muscle-invasive urothelial cancer.

Faster Corticosteroid Tapering Safe in Relapsed/Refractory MM by HMP Global